The pBS31' vector was acquired from Thermo Scientific. The WT human DNMT3A1 complementary DNA (cDNA) was obtained from Origene (NM_175629.1), and subcloned into pBS31' using the EcoRI site. The transgene was sequenced in full before proceeding. An approximately 6 Kb DNA fragment retaining the tetracycline regulatory region, CMV minimal promoter, DNMT3A cDNA, and rabbit beta globin polyA tail was liberated using a BglII/PvuI double digest. Pronuclear injection of purified DNA into C57Bl6/J zygotes was used to generate mice with random integration of the transgene. Founders were identified with PCR and expressing lines were screened by mating to Rosa26-M2 "rtTA" mice, and subjecting doubly transgenic bone marrow cells to 1ug/ml Dox in vitro for 48 hours, resolving the lysates on SDS PAGE gels, and transferring to nitrocellulose membranes for western blot analysis of DNMT3A expression. One transgenic line was used for all subsequent studies.
and stained with 1 µl Sytox red per 1 ml of cells for 15 min at 4°C. Sorting was performed on a modified Sony Synergy SY3200 (Sony Biotechnology, San Jose, CA) updated to 24 parameters. Winlist version 8 software was used for data acquisition and analysis (Verity Software House, Topsham, ME).
Whole Genome Bisulfite Sequencing (WGBS)
WGBS was performed as described in Cole et al (3) . Briefly, whole-genome bisulfite-converted sequencing libraries were generated with the Epigenome library preparation kit, or the Accel-NGS Methyl-Seq DNA library kit (Swift Biosciences, #30096). Indexed sequencing was performed on Illumina HiSeq instruments and reads were mapped with Biscuit (version 0.1.4.2016.03.30 https://github.com/zwdzwd/biscuit) using default parameters. Duplicates were marked, VCFs were generated using 'biscuit pileup' (params: -q 20) and then converted to CpG bed files. This pipeline code is available at: https://gist.github.com/chrisamiller/55f90f72382e68775541d3c8d48f3f79 (4) .
Identification of differentially methylated regions (DMRs)
The program 'metilene' (5) was used to analyze the raw methylation ratios at all CpGs to identify differentially methylated regions (DMRs), requiring >10 CpGs and a mean methylation difference between groups of >0.2. DMRs were filtered to retain those with false discovery rate (FDR) <0.05, and adjacent DMRs <50 bp apart were merged. Following these procedures, methylation data from individual CpGs were imported into R as bsseq objects (6) for manipulation and analysis, which included 'smoothing' using the BSmooth function with the parameters 'ns=35 and h=500' to impute missing methylation values for visualization. All statistical procedures and analysis used raw methylation ratios (or methylation counts) from individual CpGs, or summed data for CpG clusters or DMRs. For visualization purposes, DMRs were scaled to a common width before averaging, in order to preserve local structure (i.e. "canyon walls"). The bars representing DMRs in the "canyon plots" (see Figures 1D, 2B , 3C-F) represent the span of those scaled DMR regions, to differentiate them from the flanking sequence. These methods have been described in detail previously (3, 7) .
Motif analysis
Motif enrichment analysis for de novo motifs in the differentially methylated regions was performed using findMotifsGenome.pl of HOMER v4.5 (8) , using the '-size given' parameter.
Total RNA sequencing, processing, and analysis
Total RNA-sequencing of Dnmt3a deficient and Dnmt3a null-3A addback mice was performed using the Illumina TruSeq Stranded Total RNA Library Kit on DNase-treated RNA. Samples were ribo-depleted, purified, and fragmented at 94°C for 8 min. First-strand and second strand cDNA synthesis were then performed, followed by bead-based DNA purification, A-tailing, and adapter ligation. Library fragments were then bead-purified and amplified 7-8 cycles with sample-specific indexed primers. Sequencing was performed on an Illumina 2500 instrument to obtain 2 x 100 bp or 2 x 125 bp reads. Sequence data were processed from the raw sequencing reads using the tophat (version 2.0.8 (9)) to generate split read alignments, and expression values for mouse genome (mm9) were calculated with stringtie (10) using default parameters for stranded, paired-end data, as described by Spencer et al (7) .
Differential gene expression analyses for bulk RNA sequencing
Differentially expressed genes were identified using Trimmed mean of M (TMM) normalized counts per million (CPM) between the Dnmt3a deficient vs. wild type and Dnmt3a null-3A addback mice fed normal chow vs. dox chow. TMM calculates a linear scaling factor, di, for sample i, based on a weighted mean after trimming the data by log fold-changes (M) relative to a reference sample and by absolute intensity (A). This method is implemented in the R Bioconductor package edgeR (11, 12) and was used with default parameters. Multiplicity correction is performed by applying the Benjamini-Hochberg method on the p-values, to control the FDR. The list of genes with significant variation in expression levels was generated on the basis of a 0.05 FDR criterion as a significant cutoff.
Single-cell RNA library construction and sequencing. Cells were processed using the 10x
Genomics Chromium Controller and the Chromium Single Cell 5′ Library & Gel Bead Kit (v2.0) following the standard manufacturer's protocols (https://tinyurl.com/y96l7lns). Samples were then sequenced on the Illumina NovaSeq (2 × 150 paired end reads), yielding a mean of 486,655,675 reads per sample (Dataset S8). Transcript alignment and counting were performed using the Cell Ranger pipeline (10x Genomics, default settings, Version 3.0.1). Using a nearestneighbor algorithm implemented in R (version 3.5.1), cells were annotated according to the Haemopedia expression atlas of hematopoietic cell types (13) using code available here:
(https://github.com/genome/docker-scrna_lineage_inference). Using Partek Flow software, we defined cells that contained fewer than 250 expressed genes, less than 500 total reads, or more than 10% mitochondrial transcripts, and they were removed from subsequent analyses. For each cell, expression of each gene was normalized to the sequencing depth of the cell, scaled to a constant depth (10,000), and log-transformed. Dimensionality reduction and visualization were performed with the t-SNE algorithm. Differentially expressed genes were determined using the ANOVA (Limma-trend) algorithm and defined as having an FDR of £ 0.01 and a fold change of ³ 2 or £ -2.
Quantification and Statistical Analysis
Statistical analysis was performed using either the software indicated above or in R. Hypothesis testing in R was performed using chi-square tests for categorical variables, t-tests for continuous variables, Wilcoxon signed-rank tests for comparing means of gene expression quartiles, or Fisher's exact test for differences between proportional data (i.e. lineage fractions).
All reported significance metrics are corrected for multiple testing by Benjamini-Holm (FDR), Bonferonni or Yates methods (p values) unless otherwise noted.
Deposition of sequence data
All sequencing data for all studies were deposited to the NCBI (BioProject ID PRJNA483874). Table S2 for the values used to create this figure. Expression data was derived from the Dnmt3a +/+ vs. Dnmt3a -/whole bone marrow samples from scRNA-seq data (Figure 4 and Table S3 ). Average levels of expression were significantly greater in Q1>Q2>Q3>Q4 for both Dnmt3a +/+ vs. Dnmt3a -/samples. For the comparisons between quartiles, an unpaired Wilcoxon signed-rank test was applied. There was also significantly lower average gene expression in Dnmt3a -/samples (red) as compared to Figure S10 
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